

1 **Implementation outcomes of tuberculosis digital adherence technologies: a**
2 **scoping review using the RE-AIM framework**

3
4

5 **Authors:**

6 Chimweta I Chilala¹, Nicola Foster¹, Shruti Bahukudumbi², Mona S. Mohamed³, Miranda Zary³, Cedric
7 Kafie³, Barbie Patel², Genevieve Gore⁴, Kevin Schwartzman³, Ramnath Subbaraman^{2,5}, Katherine
8 Fielding¹

9

10 **Affiliations:**

11 ¹TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom

12 ²Department of Public Health and Community Medicine and Center for Global Public Health, Tufts
13 University School of Medicine, Boston, United States

14 ³McGill International Tuberculosis Centre, Research Institute of the McGill University Health Centre,
15 Montréal, Canada

16 ⁴Schulich Library of Physical Sciences, Life Sciences, and Engineering; McGill University, 16
17 Montréal, Canada

18 ⁴Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, United
19 States

20

21 **Corresponding author:**

22 Katherine Fielding, PhD

23 London School of Hygiene & Tropical Medicine, Keppel St, London, United Kingdom, WC1E 7HT

24 Email: katherine.fielding@lshtm.ac.uk

25

26

27

28

29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract (300/300 words)**

2

3 Introduction:

4 Globally, tuberculosis (TB) remains one of the leading infectious causes of death, with 1.3 million
5 deaths. Digital adherence technologies (DATs) have the potential to provide person-centred care and
6 improve outcomes. Using the RE-AIM framework, we conducted a scoping review of DAT
7 implementations for TB treatment.

8

9 Methods:

10 We searched eight databases for papers published between January 2000 and April 2023, using
11 keywords for ‘tuberculosis’ and ‘digital adherence technology’. Articles meeting prespecified inclusion
12 criteria and containing data on RE-AIM domains were included (PROSPERO-CRD42022326968). We
13 defined ‘reach’ as comprising cellphone ownership and engagement by people with TB (PWTB) with
14 DATs, ‘adoption’ as engagement by healthcare providers with DAT programs, ‘implementation’ as the
15 fidelity of the DAT program implemented, and ‘maintenance’ as longer-term uptake of DATs.

16

17 Results:

18 Of 10,313 records, 105 contributed to the synthesis. DATs included SMS, phone, 99DOTS, video-
19 supported therapy and pillboxes. For ‘reach’, across various settings, cellphone access varied from 50-
20 100% and 2-31% of PWTB were excluded from accessing DATs due to technology challenges. 36-100%
21 of PWTB agreed to use a DAT. The weighted mean of DAT engagement over dose-days was 81% for
22 SMS, 85% for phone, 61% for 99DOTS, 87% for pillbox and 82% for VST. Concerning ‘implementation’,
23 the fidelity of DAT implementations was affected by technological issues such as cellphone coverage,
24 DAT malfunction and provider-facing issues; including failure to initiate intensified patient
25 management following low DAT engagement. Findings related to RE-AIM dimensions of ‘adoption’ and
26 ‘maintenance’ were limited.

27

28 Conclusion:

29 Our findings suggest that the ‘reach’ of DATs may be limited by a cascade of barriers, including
30 limitations in cellphone accessibility and suboptimal sustained DAT engagement by PWTB. Video and
31 pillbox DATs have higher levels of engagement. Implementation challenges included technological and
32 provider-facing issues. Improving implementation outcomes may be important for TB DATs to achieve
33 broader public health impact.

34

35

36

1 Introduction

2

3 Despite a remarkable global recovery in TB notifications reporting, diagnosis and treatment following
4 the disruptive impact of the COVID-19 pandemic, tuberculosis (TB) remains the leading cause of death
5 from a single infectious agent accounting for nearly 1.3 million deaths annually [1]. Completion of
6 tuberculosis treatment and treatment adherence are crucial to the success of tuberculosis care
7 programmes broadly. In 2022, treatment success rates were 85% worldwide, though success rates vary
8 substantially by country and for different subpopulations of people with TB [1]. For the last few
9 decades, directly observed therapy (DOT) was promoted as a strategy for monitoring adherence to
10 medications by people with TB to address the persistence of the TB global pandemic [2]. DOT requires
11 patient self-management, frequent and timely monitoring, and surveillance at the health facility which
12 places a substantial burden on people with TB and providers.

13

14 Digital adherence technologies (DATs), such as short message service (SMS) reminders, feature (non-
15 smart) phones, video-supported therapy (VST), smart digital pillboxes and ingestion sensors, have the
16 potential to address these concerns [3,4]. Understanding their effects on TB care has resulted in a large
17 number of evaluations, particularly over the last 10 years, though evidence for effectiveness on
18 treatment adherence and outcomes showed varied results and with limited generalisability [5,6]. VST
19 evaluations, predominantly conducted in upper-middle and upper-income settings, suggest the DAT is
20 promising, as do approaches that combine DATs with other non-digital approaches. DATs evaluated in
21 low and lower-middle-income settings which focussed on pillboxes, SMS reminders and medication
22 sleeves with phone calls (branded as “99DOTS”), show no tangible benefits on treatment outcomes.
23 Implementation of DATs in a range of settings, including the coverage of such technologies and fidelity
24 to the planned interventions from the provider's perspective, is important for understanding the
25 successes and challenges in delivering these new approaches for TB care, and particularly important
26 given the mixed effectiveness results. Evidence synthesis for DAT implementation has not been
27 conducted to date. The RE-AIM framework, based on five dimensions, reach, effectiveness, adoption,
28 implementation, and maintenance, is used to characterise the public health impact of an intervention
29 [7].

30

31 Using the RE-AIM framework, we conducted a scoping review and meta-analysis of the
32 implementation of DATs for TB and *M. tuberculosis* infection treatment in high-income, and low-and-
33 middle-income countries. The focus of our scoping review was on the quantitative indicators used

- 1 within this framework, assessing reported implementation outcomes. A companion review covers
- 2 contextual factors that influence DAT implementation [8].

1 **Methods**

2 *PICOS framework and scoping review design*

3 We followed a rigorous systematic methodology, having originally designed this study as a systematic
4 review, then later modified it to a scoping review due to high heterogeneity in the studies and
5 measures of interest. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-
6 analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines (supplementary appendix 1). [9]. Our
7 published review protocol is available from PROSPERO [CRD4022326968]. Assessment of the risk of
8 bias for the included studies has not been conducted. We used the Population, Intervention,
9 Comparison, Outcomes, and Study (PICOS) framework to define our study population, intervention of
10 interest, comparator (supplementary appendix 2; Table S1) and study design and used the RE-AIM
11 framework to identify and analyse the implementation-related outcomes from studies using DATs.
12 The study populations included people with TB, people with *M. tuberculosis* infection and other
13 individuals such as healthcare workers, programs managers, or policymakers (subsequently referred
14 to as healthcare providers [HCP]) who are involved in the implementation of DATs within health
15 systems for TB care. Interventions of interest were DATs which can aid the monitoring and support of
16 TB medication adherence. These technologies included SMS, feature phone and smartphone
17 technologies, digital pillboxes, VST, web-based approaches and ingestion sensors. Included studies
18 may or may not have had a comparator group. We included observational and randomised studies in
19 this review (Table S1).

20

21 *Search Strategy*

22 We systematically searched Medline/Ovid, Embase, Cochrane Central Register of Controlled Trials,
23 CINAHL, Web of Science, clinicaltrials.gov, and Europe PMC, using keywords for “tuberculosis”
24 (including both active TB disease and *M. tuberculosis* infection) and “digital adherence technology”
25 (Table S2). A Health Librarian conducted the search. Our initial search was from January 1st 2000 to
26 April 1st, 2022, and was then updated to cover the period from 2nd April 2022 to 25th April 2023. No
27 language restrictions were applied. Following an initial attempt, conference abstracts and grey
28 literature, though listed in our protocol as potential data sources, were not retrieved as the quality of
29 the data from these sources lacked the necessary detail for our implementation indicators.

30

1 *Study Screening and Data Extraction*

2 The search results were imported into Endnote where duplicates were removed and underwent two-
3 level blinded screening by two authors (CC, SB, MS, CK, MZ, NF) independently in Rayyan (Rayyan,
4 Cambridge USA). Conflicts were resolved by the senior investigators (KF, RS, KS). The first level of
5 screening involved title and abstract screening and the second level was full-text screening against
6 prespecified inclusion/exclusion criteria (Table S3). We were inclusive in the second screen, with
7 reasons for exclusion being: (i) not satisfying our case definition for TB and/or DATs; (ii) wrong
8 publication type (systematic review, study protocols, trial registrations); (iii) no primary data related to
9 quantitative implementation outcomes; or (iv) duplicates. Reasons for exclusion were noted and
10 summarised in the PRISMA flow chart (Figure S1).

11
12 For articles satisfying the first and second-level screens, quantitative outcome data on the dimensions
13 of the RE-AIM framework were extracted from the full text using a standard extraction form. One
14 reviewer extracted the data which was verified by a second reviewer, and any conflicts were resolved
15 by discussion between the reviewers, with input from a third reviewer when necessary. The extracted
16 data included the following: study characteristics (name of the author, publication year, country, study
17 design, study setting, the aim of the study); participant characteristics (TB disease, *M. tuberculosis*
18 infection, drug resistance, HIV status); DAT intervention (type of DAT, duration); and quantitative
19 outcomes data using the RE-AIM framework, as described below. Some articles initially eligible for data
20 extraction were subsequently excluded, following attempted data extraction, as no RE-AIM
21 quantitative outcomes data were reported. To confirm the validity of our search and identify any
22 outstanding references, we extracted references from all systematic reviews identified from our initial
23 search (see exclusion criteria), and these references were screened for eligibility. For one article,
24 initially included as a preprint, we abstracted data from the supplement of the subsequently published
25 article [10].

26 27 *RE-AIM framework*

28 The domains of the RE-AIM framework are 'reach', 'effectiveness', 'adoption', 'implementation', and
29 'maintenance'. We defined reach, among people taking treatment for TB disease or infection, as
30 measures of engagement with a DAT into three categories: A – the proportion of people with the
31 potential to use or receive DATs (including requirements for cellphone access); B - the proportion of
32 people with any uptake of or engagement with DATs; C- the quality and/or duration of engagement
33 with DATs. Adoption refers to measures of DAT engagement by HCPs. Implementation was measured
34 through the fidelity of the intervention, that is, the extent to which the DAT intervention is operated

1 as intended. Implementation outcomes were grouped into technology-related (the extent to which the
2 DAT functioned as intended) and provider fidelity-related (the extent to which HCPs delivering the
3 intervention adhered to the planned/designed intervention). Finally, the extent to which DATs become
4 integrated into routine care was captured under maintenance (Table S4). The effectiveness domain
5 was covered in a related review [6].

6

7 Though not originally planned, we also extracted as part of reach category A data on cellphone sharing,
8 defined as shared vs own phone not shared, by people on treatment for TB disease or infection or
9 potentially eligible for TB preventive therapy (e.g., household contacts of a person diagnosed with
10 TB).

11

12 *Analysis*

13 DAT interventions which included more than one component, for example, digital pillboxes with SMS
14 reminders, were analysed based on the DAT considered as primary to the intervention. Binary
15 outcomes, reflecting a consistent measure of reach indicators A and B, were summarised as the
16 number of individuals satisfying the indicator divided by the relevant denominator, alongside a 95%
17 confidence interval and displayed using forest plots. Where relevant, plots were stratified by income
18 level of the country where the study was conducted, grouped as lower- or lower-middle- (L/LMIC),
19 upper-middle- (UMIC), or high-income (HIC); DAT type; or TB type. Confidence intervals for
20 proportions were exact Clopper-Pearson intervals, with a continuity correction of 0.5 applied for
21 measures with zero cells.

22

23 For reach C, two main measures were extracted to capture DAT engagement over the entire treatment
24 period: a binary measure of the proportion of individuals with DAT engagement greater than a given
25 threshold as reported by the original studies (i.e., a cut-off point; for example, >80%, >90%, etc.) and
26 a measure of dose-days with DAT-engagement. When binary measures were reported as less than a
27 cut-off, the data were converted to a positive measure. A pooled estimate, by engagement level,
28 across studies was calculated using random effects meta-analysis, across all DAT types. In sub-group
29 analyses by DAT types, we opted not to produce summary measures due to the small number of
30 estimates per DAT type and cut-off point. Publication bias was assessed using Doi plots in keeping with
31 guidance for meta-analyses of proportions, using the Luis Furuya-Kanamori (LFK) index [11–13]. The
32 second measure of dose-days with DAT-engagement was extracted from reports either as an average,
33 often the arithmetic mean, of the measure across individuals or as an overall proportion (DAT-
34 engagement days/all dose-days), ignoring individuals; for both measures, a standard error accounting

1 for clustering was often not reported and could not be calculated using the available data. We
2 therefore have summarised these data graphically using a bubble plot with the size of the bubble
3 proportional to the number of individuals contributing to the measure. Except for studies with more
4 than one DAT intervention group, where more than one related measure was extracted from an
5 article, we chose a single measure that was considered most consistent with dose-days with DAT
6 engagement. Any extracted data that did not fit into the measures described above were tabulated
7 by income level, DAT type, and TB type.

8

9 We found limited findings on adoption and maintenance indicators; therefore, these RE-AIM
10 dimensions were summarised narratively. For implementation, indicators were ordered by DAT type
11 and whether it was a technology issue or related to HCP fidelity to the intervention. Technology issues
12 were grouped, where possible, from the person with TB or HCP perspective.

13

14

15

1 **Results**

2

3 *Characteristics of the included studies*

4 Following de-duplication, 10,313 articles were identified, of which 779 satisfied the first screen and
5 771 were assessed for eligibility. Data extraction was attempted for 185 eligible articles, including one
6 preprint that was not originally identified, though did fall within the database search period (Figure
7 S1). The reference search from 68 systematic reviews yielded no articles missed in our main search. Of
8 the 185 articles from which data extraction was attempted, 80 were excluded as no relevant data were
9 found, leaving 105 contributing to the quantitative analysis; 90 to reach, two to adoption, 28 to
10 implementation, and three to maintenance (Figure S1). Five studies of 105 only contributed to
11 unplanned data summaries for cellphone ownership.

12

13 Of the 105 articles, 45, 25, and 35 were from L/LMIC, UMIC, and HIC, respectively, and 91 involved
14 treatment for tuberculosis disease. The primary DAT types reported were VST (34), digital pillbox (22),
15 phone (20), SMS (12), 99DOTS (7), web-based app (5) and ingestion sensor (2). In addition, three
16 articles reported on more than one DAT type, with each DAT type used by a subset of the cohort
17 receiving TB treatment; digital pillbox and SMS, digital pillbox and 99DOTS, and VST, digital pillbox and
18 99DOTS [14–16]. Findings from VST studies mostly came from HIC settings while SMS, pillbox and
19 phone-based technologies were largely used in L/LMICs and UMICs. 99DOTS was predominantly used
20 in L/LMIC settings and digital pillboxes were used in the widest range of country income settings. See
21 Table 1 and Table S10.

22

1 Table 1. Summary of included reports by DAT type, RE-AIM indicators, country income level, and calendar year (n=105)

2

	HIC				UMIC				L/LMIC				Overall	
	2000-2017		2018-2023		2000-2017		2018-2023		2000-2017		2018-2023		n	RE-AIM
	n	RE-AIM	n	RE-AIM	n	RE-AIM	n	RE-AIM	n	RE-AIM	n	RE-AIM		
Total number	15	[R; A; I]	20	[R; I; M]	5	[R; I]	20	[R; I; M]	12	[R; I]	33	[R; A; I]	105	[R; A; I; M]
SMS	-		1	[R]	3	[R; I]	2	[R]	3	[R; I]	3	[R; I]	12	[R; I]
Phone	1	[R]	-		-		5	[R]	3	[R; I]	11	[R; I]	20	[R; I]
99DOTS	-		-		-		-		-		7	[R; I]	7	[R; I]
Pillbox	4	[R; I]	2	[R]	-		9	[R; I; M]	3	[R; I]	4	[R]	22	[R; I; M]
VST	9	[R; A; I]	15	[R; I; M]	1	[R]	3	[R; I]	2	[R; I]	4	[R; I]	34	[R; A; I; M]
Ingestion sensor	1	[I]	1	[R]	-		-		-		-		2	[R]
Web-based Apps	-		1	[R, A]	-		1	[M]	1	[R]	2	[R]	5	[R; A; M]
>1 DAT intervention ¹	-		-		1	[R; I]	-		-		2	[R; I]	3	[R; I]

3

4

5

6 n represents the number of reports; HIC high-income country; UMIC upper middle-income country; L/LMIC low/low middle-income country; DAT digital adherence
7 technology; SMS short message service; VST video-supported therapy; R Reach; A Adoption; I Implementation, M Maintenance; ¹ these reports looked at more than one
8 DAT type, with each DAT type used by a subset of the cohort receiving TB treatment (digital pillbox, SMS, or both [16]; digital pillbox or 99DOTS [14]; and VST, digital pillbox
9 or 99DOTS [15]). Note: Wei et al (2023) listed under pillbox in this table. “99DOTS” is a brand name for a DAT which uses medication sleeves with phone calls by the person
10 with TB to document treatment adherence. Five studies only contributed to the unplanned data summaries for cellphone ownership.

1 *Reach A—Cellphone access among people with TB*

2 We found that across a range of settings, access to cell phones varied from 50% (15/30) to 100%
3 (574/574). Smartphone access accounted for some of the lower proportions of access in studies
4 predominantly from HIC settings (Figure 1a). Between 2% (1/54) to 31% (277/891) of people with TB
5 were excluded from studies due to technology challenges such as the inability to regularly send SMS
6 and lack of telephone signal or internet. This was more common in L/LMIC than in HIC settings (Figure
7 1b). Five studies, three of which were from UMIC, reported the percentage of people with TB not
8 eligible for using a smart pillbox due to communication impairment or being too ill (Table S5). This
9 proportion ranged from 2% (18/891) - 9.5% (21/221) [16–20]. From the additional unplanned data
10 collection, we found that shared phone access ranged from 4% (5/122) to 50% (98/197) in L/LMIC (8
11 studies) and 13% (19/145) - 39% (49/125) in UMIC (3 studies). See Figure S2.

12

13 [INSERT FIGURE 1]

14

15 TB tuberculosis, LTBI latent tuberculosis infection; DAT digital adherence technology; SMS short message service;
16 L/LMIC low/low middle-income country; UMIC upper middle-income country; HIC high-income country.

17

18 *Reach B—Any DAT engagement by people with TB*

19 Eight studies reported the proportion of people on TB disease treatment (plus one study for *M.*
20 *tuberculosis* infection treatment) who agreed to use the DAT (Figure 2a). The percentages ranged from
21 36% (110/308) [21] to 100% (15/15), with the vast proportion being greater than 85%; percentages
22 were similar by DAT type. The low uptake for VST in the study by Casalme and colleagues, conducted
23 in Thailand, was hypothesized to have been due to the reluctance of people with TB and providers to
24 try out new technologies [21]. Of those offered a DAT, the percentages who used the DAT at least once
25 ranged from 33% (2746/8322) for 99DOTS to 95% (70/74) for phone-based DATs, including responses
26 by people with TB and family members (Figure 2b). Early engagement with a DAT was measured during
27 the first 3 months of treatment (range range 1-90 days). Measures ranged from 60% (in a 99DOTS
28 intervention where a call was made on day 84) [22] to 89% (in a pillbox intervention were-engagement
29 over the first 90 days for *M. tuberculosis* infection treatment was monitored [23]). Other varied
30 measures of reach B are summarised in table S6.

31

32 [INSERT FIGURE 2]

33

34 TB tuberculosis, DAT digital adherence technology; SMS short message service; VST video-supported therapy,
35 99DOTS

36

1 Four studies reported on the percentage of people with TB who stopped using the DAT during the
2 treatment period for reasons other than death or loss to follow-up; for SMS and/or pillbox
3 interventions the percentages ranged from 1% (12/1020) to 9.3% (9/208) [17,24,25] (Figure S3). For a
4 VST study in the Philippines, 39.1% (43/110) stopped the DAT before they ended treatment, with 26/43
5 due to HCP and/or participant's decision [21].

6

7 *Reach C—Sustained DAT engagement by people with TB*

8 Several studies reported engagement as a proportion of individuals who achieve a specified level of
9 engagement with the DAT. A total of 31 observations (17 studies) were included in the meta-analysis
10 of the proportion of DAT engagement, by binary level of engagement (Figure S4). At a threshold of
11 100% engagement, the summary measure for the percentage of participants exhibiting perfect
12 engagement was 29% (95%CI: 21%; 38%). The proportion of participants engaging with the DATs
13 increased as the cut-off point reduced: at >95% cut-off, 73% (95%CI: 61%; 85%) of participants showed
14 sustained engagement with DATs; at >90% cut-off, 85% (95% CI: 76%; 95%) of participants; at >85%
15 cut-off, 85% (95% CI: 77%;94%) of participants; and at >80% cut-off, 88% (95%CI: 75%;100%) of
16 participants. In the subgroup analysis by DAT type, we found similarly that the proportion of individuals
17 who achieved the level of engagement increased as the level decreased and that this was similar
18 between DAT types (Figures S5-9). When assessing publication bias in the meta-analysis, the LFK index
19 was less than +/-2 (-0.77) confirmed visually on the Doi plot, suggesting that effect estimates were
20 fairly symmetrical, providing limited evidence of publication bias (Figure S11).

21

22 Other studies reported the percentage DAT engagement measured over total dose-days, either as the
23 number of days with DAT engagement divided by the total days of observation ignoring the individual-
24 level or an average across individuals (Figure 3, data by DAT type and income setting). The weighted
25 average of percentage DAT engagement was 60.7% (n=6709) for 99DOTS, 80.9% (n=1201) for SMS,
26 81.6% (n=2179) for VST, 84.9% (n=1214) for phone and 88.3% (n=4784) for the pillbox.

27

28 [INSERT FIGURE 3]

29

30 The plot summarises the percentage of DAT engagement over total dose days for 54 observations from 41 studies
31 included in this analysis. Studies included for SMS interventions [16,24,26,27]; Phone [28,29]; 99DOTS [15,30–
32 32]; Pillboxes [10,15,16,20,33–40]; VST [15,41–60]; and Ingestion Sensors [61]. For Wei (2024) and Liu (2015)
33 pillbox openings were supplemented with pill counts so not all adherence was measured based on engagement
34 with the digital adherence technology [10,16]. For de Groot (2022) the measure of DAT engagement as pertaining
35 to 99DOTS and Pillbox has been adapted to remove manual dosing [15].

36 Country income level is indicated by the colour of the bubble and the size of the bubbles indicates the number
37 of people with TB whose dose-days were included. The red line represents the average of percentage
38 engagement, weighted by the sample size of the contributing study. The weighted means of DAT engagement by

1 DAT type and country income level (number of persons with TB data included) are summarised in the table
 2 below:

	SMS	Phone	99DOTs	Pillbox	VST
Number of studies	4	2	4	12	21
Number of data points	4	2	9	15	24
	Mean (n)*	Mean (n)*	Mean (n)*	Mean (n)*	Mean (n)*
Overall	80.9% (1201)	84.9% (1214)	60.7% (6709)	86.6% (4784)	81.6% (2179)
HICs	93.7% (170)	N/A (0)	N/A (0)	91.7% (145)	81.8% (1875)
UMICs	79.3% (996)	84.9% (1214)	80.0% (22)	88.7% (3609)	72.6% (10)
L/LMICs	63.0% (35)	N/A (0)	60.7% (6687)	78.8% (1030)	80.8% (294)

3 L/LMIC low/low middle-income country; UMIC upper middle-income country; HIC high-income country; SMS
 4 short message service; VST video supported therapy; * Mean (n) represents the weighted mean (number of
 5 persons with TB).
 6
 7

8 Measures of DAT engagement that were varied or non-standard, are summarised in Table S8. These
 9 include data on adherence to a bedaquiline-based treatment regimen using pillboxes and a cut-off of
 10 >90% and >85% [20,62].
 11

12 *Adoption*

13 We found few studies that captured adoption quantitatively. Himachal Pradesh state in northern India
 14 launched its 99DOTs program in 74 TB units between 2018-9. The percentage of people with TB in
 15 each TB unit who were initiated on 99DOTs by HCPs, was measured by a proxy, which was people with
 16 TB calling 99DOTs at least once. This varied from 0.0% to 97.5% [30]. This variation in 99DOTs uptake
 17 could be interpreted as a measure of HCP adoption of the technology, assessed at the health centre
 18 level. A second study conducted in South Australia reported on the roll-out of a videophone approach
 19 for direct treatment observation from 2006 (0% [0/74] of people with TB used video service) to 2010,
 20 where 52% (30/58) of people with TB used video service [63].
 21

22 *Implementation*

23 For the implementation RE-AIM dimension, several findings were reported related to technology
 24 fidelity, the extent to which technology functioned as intended, and provider fidelity, the extent to
 25 which HCPs executed the intervention as designed/planned. Technological challenges were broadly
 26 categorised into those encountered by people with TB (e.g., phone malfunctions, flat batteries or
 27 accessories, malfunction of Apps and software, inability to use the DAT), connectivity issues (e.g., slow
 28 internet, network failure, or transmission failure) or those encountered by providers (such as poor
 29 video quality, inability to access adherence monitoring software or app) (Table 2 and Table S9).
 30

1 Table 2: Summary of implementation indicators by DAT type
2

DAT	Person	Indicator	Number of studies	Author (year)
SMS	Person with TB	Problems with phone (eg., lost, stolen, unable to charge)	1	Hermans (2017) Gashu (2021), Dessie-Gashu (2020), Mohammed (2016), Hermans (2017), Bassett (2016)
		Messages not received/delivered	5	
Phone	Person with TB	Phone call failure (including due to network issues)	2	Daftary (2017), Katende (2022)
99DOTS	Person with TB	SMS not received/sent	2	Kiwanuka (2022), Efo (2021)
	Healthcare provider	Problems with access to adherence data due to no electricity, poor network, App not working	1	Guzman (2023)
Pillbox	Person with TB	Incorrect use of box	1	Liu (2015)
		Power issue	1	Liu (2015)
		Reminders not received	1	Acosta (2022)
		Incorrect reminders	1	de Sumari-de Boer (2016)
	Healthcare provider	Box incorrectly set-up	1	Liu (2015)
		Problems with access to adherence data due to poor network, App not working	1	Guzman (2023)
	General	Pillbox replaced	1	Liu (2015) Liu (2023), Trajman (2010), Wang (2020)
		Missing data from pillbox	3	
VST	Person with TB	Problems with uploading videos/app	5	Guo (2020), Chuck (2016), Nguyen (2017), Garfein (2018), Sekandi (2020)
		Experiencing cellphone reception/transmission issues	2	Garfein (2018), Hoffman (2010), Sekandi (2020)
		Problems due to lost phone	1	Hoffman (2010)
		Forgetting to send video	1	Kumwihar (2022)
		Stopped VST due to technology issues	1	Casalme (2022)
	Healthcare provider	Dissatisfied with video quality	1	Guo (2020)
		Problems with video DAT	1	Bendiksen (2020)
Ingestion sensor	General	Wearable component was not working/identified by App	1	Belknap (2013)
Provider fidelity		Reported on components of the intervention not delivered as planned	6	Liu (2015), Wang (2020), Kiwanuku (2020), Wei (2023)*, Liu (2023), Bassett (2016)

3 VST video-supported therapy; SMS short message service; DAT digital adherence technology; 99DOTS

1 * Wei study was included as a preprint (2023) [64], though the data abstracted for this summary are from the
2 supplement of the subsequently published article (2024) [10].
3

4

5 Problems with implementing SMS-based interventions were reported by five authors [65–69]. Issues
6 reported by people with TB included the inability to charge the phone battery, damaged phones, and
7 no longer being able to access a shared phone. Problems with automated SMS delivery or receipt were
8 also described. Two articles reported on technology measures with the 99DOTS intervention [14,70].
9 The percentage of SMSs sent among eligible days was 90%, and the percentage of SMSs received on
10 handsets was very high (>99%). In a large multi-country study, 59% (41/70) of HCPs had problems
11 accessing the adherence data (on a digital platform) at some point during the study period, due to lack
12 of electricity, poor network, or the app not working, though a high percentage could access the
13 adherence data daily (92%; 56/61). Seven studies reported implementation challenges with the pillbox
14 [14,16,26,33,36,71,72]. Issues included incorrect pillbox set-up, lack of power, pillbox failure, and
15 incomplete pillbox data. Similar problems with HCPs accessing adherence were reported, as for
16 99DOTS. Challenges with implementing VST were reported by nine authors, the majority from HIC
17 settings [21,43,44,47,58,60,73–75]. Technology problems experienced by people with TB primarily
18 involved VST platform/application difficulties, including uploading of videos. The percentage of people
19 with TB experiencing this at least once ranged from 40-89%, though frequent problems were rare (8-
20 11%). Reasons for videos not being transmitted included phone malfunction, phone loss, battery and
21 App issues, and lack of or slow internet.

22

23 Measures of provider fidelity reflected adherence to the planned intervention by HCPs delivering the
24 intervention (Table S9). The data extracted mainly focused on studies where the intervention included
25 a protocolised change in management, such as a switch of people with TB to more intensive
26 supervision and/or in-person DOT, following a display of low DAT engagement. Three studies from
27 China that implemented a change to management reported on such issues [16,36,72]. The percentage
28 of participants who started intensive management (regular visits by village/town doctor), of those
29 eligible, ranged from 15.1%-82.1% (4 study arms; [16,36]). Despite the reported percentage being high
30 in the latter study, this was not corroborated by participant self-report of change in the average
31 number of visits per month, after intensified management. The percentage of participants who started
32 DOT (daily observed treatment by a health practitioner), of those eligible, ranged from 3.8% (9/240)
33 to 53.5% (53/99) [16,36,72]. Wei et al reported high levels of fidelity (>88% per month), for the change
34 to VST among those who missed >3 consecutive doses, or for whom a doctor had concerns about their

1 adherence [10]. Bassett et al reported fidelity of 72% (694 out of 976 participants) for the receipt \geq 5
2 call attempts [76].

3

4 *Maintenance*

5 An assessment of TB patient care and support policies in high-burden countries was conducted in 2018,
6 with responses from 23 of 30 high-TB-burden countries. Digital interventions to support treatment
7 adherence which were incorporated into the National TB Program policies included VST (3/23),
8 pillboxes (2/23), 99DOTS (4/23), two-way SMS (2/23), and one-way SMS (2/23). Few countries,
9 however, reported using these technologies, and often only in small-scale pilot studies [77]. A survey
10 conducted in 2015 of US states, large cities, and US-affiliated Pacific Islands indicated that 42%
11 (47/113) were using VST at that time, while 36% (41/113) had plans to do so [78]. A phased
12 implementation of pillboxes for people with DS-TB adults was conducted across three provinces (138
13 counties) in China, beginning in 2017. By January 2019, all counties in those provinces were
14 implementing pillboxes [79].

15

16

1 Discussion

2

3 In this scoping review, we summarise quantitative findings of implementation outcomes of TB DATs
4 using the RE-AIM framework, with most findings about dimensions of reach and implementation. Our
5 findings provide insights into implementation challenges that might influence the effectiveness,
6 accuracy, and real-world public health impact of these technologies. Concerning reach, successful DAT
7 engagement by people with TB requires that multiple conditions must be fulfilled, including adequate
8 and consistent access to cellphones or DATs, eligibility to receive a DAT, early DAT engagement, and
9 sustained DAT engagement. We found at least moderate challenges with, or high variability in, DAT or
10 cellphone accessibility and early and sustained DAT engagement. Together, challenges across these
11 various levels of DAT accessibility or engagement likely result in a “cascade” of problems that may
12 sometimes considerably limit the reach of DATs across the entire population of people being treated
13 for TB, as shown in studies that measured reach across multiple of these levels [18,80]. Limitations in
14 the reach of DATs may partly explain the variable effectiveness of DATs (as engagement with DATs may
15 be important to improve adherence behaviour) and the variable accuracy of DATs (as non-engagement
16 with DATs may result in non-reporting of doses taken) in different settings [6,81].

17

18 Our review also quantifies factors that inhibit reach such as lack of phone ownership, shared phone
19 ownership, communication impairment (severe illness, hearing problems), lack of telephone signal or
20 internet or “phone credit”. Secondly, relating to early and sustained engagement, the evidence
21 suggests there is a high willingness to engage with DATs initially, but the sustained engagement seems
22 to gradually reduce. It is possible that factors such as access (e.g., shared phones, unstable cellular
23 network, internet or electricity supply), equity challenges (e.g., literacy, stigma) and DAT-related issues
24 (technology fatigue, “ease of use”) could result in a reduction in engagement with the DATs. These
25 issues are detailed in the companion review of contextual factors for DAT implementations [8]. Sub-
26 optimal DAT function and cellular connectivity were common themes for facilitating conditions.
27 Challenges with the use of digital technologies and connectivity have been raised as a concern for the
28 equity of the implementation and use of DATs for TB treatment support, given that tuberculosis
29 preferentially affects people of lower socio-economic positions [82,83]. Evidence suggested that even
30 though cell phone coverage (Reach A) ranges from moderate to high (50%-100%), it is impacted by the
31 ability to use a phone such as difficulty reading and sending text messages, shared ownership of
32 phones and connectivity issues such as unreliable telephone signals or internet connection. While HIC
33 settings recorded a slightly lower proportion with access to cellphones likely because interventions
34 such as VST require more feature-rich mobile phones, in L/LMICs, access to cell phones may have been

1 more affected by the connectivity issues and sharing of phones in households. On balance, we found
2 that the proportion of people who were excluded from the use of DAT interventions was greater in
3 LMIC than in HIC settings. We also found that individuals agreeing to use the DAT and initiating the
4 DAT intervention (Reach B) was greatest among those using VST followed by pillboxes, lesser in SMS
5 and 99DOTS, and lowest in phone-based DATs. For sustained engagement (Reach C), we found a similar
6 percentage (85%) of individuals satisfying thresholds of 80, 85, and 90% of doses taken. For
7 engagement over total dose-days, 99DOTs had the lowest level (60.7%) while pillbox had the highest
8 (88.3%). We found little DAT engagement data by treatment phase. We opted not to use the
9 summaries in de Groot (2022) as it was not possible to separate digital & manual dosing by type of DAT
10 [15,15] .

11
12 Compared to metrics of reach, very few studies reported quantitative measures of adoption (a
13 measure of the interaction between technology and the HCP). However, studies that did report
14 findings found high variability in adoption at the health centre level in the few studies reporting
15 findings. A major reported challenge that may have affected reach or coverage was technology issues
16 encountered by people with TB, including connectivity challenges. The inability of the DAT intervention
17 to function as intended might have affected not only coverage but also the validation and reporting of
18 doses and therefore, their adherence levels reported. Therefore, it is important to anticipate and
19 address DAT-related problems (phone malfunctions, flat batteries or accessories, crashing apps, and
20 software) by, for example, ensuring rigorous quality control and assurance in the development of
21 devices and applications/software. An important constraint of DAT fidelity was connectivity issues,
22 which rely on third parties such as cellular network providers to ensure a stable network. In addition,
23 geographical obstacles may underpin challenges in connectivity on an individual level, especially in
24 LMICs and UMICs. Concerning maintenance, even though very few studies reported on this, it seems
25 VST, pillboxes and SMS-based interventions were the most employed. VST has been implemented
26 mostly in Western HIC and pillboxes (with or without SMS) in Asian countries.

27
28 Implementation challenges included: technology issues experienced by people with TB (problems with
29 phone batteries, broken/lost accessories, software malfunction, and DAT malfunction such as pillbox
30 failure); connectivity issues (problems with transmission of videos due to unstable internet or lack of
31 cell phone reception); and technology issues experienced by HCPs (inability to access adherence data,
32 internet access). Provider fidelity mainly focussed on the completeness of the components of the
33 intervention, such as failure to initiate intensified PWTB management following low DAT engagement.
34 Overall though we found that many studies did not report on measures of implementation or fidelity

1 to the intervention. Most reports included were research studies and few looked at the routine roll-
2 out of DATs, and therefore maintenance indicators were scarce.

3
4 This study and the companion review on contextual factors are the first, to our knowledge, to
5 systematically report on the implementation of DATs for the treatment of TB and *M. tuberculosis*
6 infection. We found one protocol paper aiming to conduct a systematic review of barriers and
7 facilitators of implementing pillboxes for TB treatment; results have not yet been reported [84].
8 Systematic reviews of the implementation of mHealth technologies using the RE-AIM framework,
9 however, have been conducted in other disease areas. In an extension to a systematic review of the
10 effectiveness of digital-supported programmes for heart disease, authors reported on RE-AIM
11 indicators from 36 publications (27 studies) [85]. They found few studies reported on maintenance
12 and information on intervention fidelity. A systematic review of studies assessing mobile phone-based
13 interventions for diabetes self-management found limited data on adoption, implementation, and
14 maintenance [86]. Strengths of our study include it being a scoping review that has been conducted to
15 a high standard, using the same methods as those used for systematic reviews, namely the systematic
16 identification and screening, and double data extraction from studies included in the review [87].

17
18 Limitations of this review include the relatively limited data available for some dimensions of the RE-
19 AIM framework, suggesting that these are areas for which more research is needed in the future. A
20 total 105 articles contributed to the quantitative synthesis of DAT implementation, using the RE-AIM
21 framework. Most data were focused on reach (90/105), followed by implementation (28/105); few
22 studies reported data on adoption and maintenance indicators. We were not able to assess the quality
23 of the studies as the included reports were often not aiming to measure our outcomes of interest,
24 though these indicators were reported as additional data from their evaluations. Other limitations
25 relate to the disparate measures used to measure DAT engagement, complicating comparability. For
26 the meta-analysis we have calculated the confidence intervals using exact Clopper-Pearson intervals;
27 this will have likely resulted in narrower confidence intervals for some studies as clustering, such as
28 individuals within health facilities, has been ignored. Given our interest was in measures commonly
29 not presented as main outcomes, we decided not to include data from published conference abstracts
30 as the data quality was anticipated to be of insufficient detail for our review, after an initial attempt.
31 We similarly did not assess the grey literature which may have contributed some information to the
32 maintenance dimension of the framework, data of which were lacking. We found no evidence of
33 publication bias when restricting to similar measures (>90% engagement) suggesting that our
34 estimates may be representative of engagement in practice. A strength of our study is that we assessed

1 data from a range of studies implemented over a period when mobile phone use and connectivity have
2 increased substantially globally. This study adds to the evidence base for DAT implementation,
3 highlighting some of the nuances between countries and measures that are important to consider in
4 planning implementation and designing new interventions.

5

6

7 **Conclusion**

8 In conclusion, this synthesis has highlighted reach and intervention fidelity challenges to DAT
9 implementations across varied country income settings and DAT types. These issues could inform how
10 DAT interventions could be adapted to increase equitable access to such technologies and improve
11 treatment outcomes.

12

1 **Contributors**

2 RS, CC, KF, and KS conceptualized the study and designed the protocol for the scoping review. GG
3 contributed to the design of the database search, advised on study conduct and conducted the
4 database search. MS, SB, CC, CK, MZ, and NF led the identification of eligible articles for the review,
5 and RS, KF, and KS resolved conflicts during the article identification process. SB, CC, KF, RS, and NF
6 extracted relevant findings from articles included in the review. KF, CC and NF organized findings,
7 conducted analyses and produced summaries. BP helped with organization and reporting of findings
8 in the supplementary appendices. CC, NF and KF wrote the first draft of the manuscript. All authors
9 provided critical revisions to the initial manuscript draft and approved the final paper.

10

11 **Funding**

12 This manuscript was supported by a grant from the Bill & Melinda Gates Foundation (grant INV-
13 038215). The funding body had no role in study design, data collection, data analysis, data
14 interpretation or manuscript writing.

15

16 **Competing interests.**

17 None declared.

18

19

1 **References – review (blue) and interpretation (black)**

2

3 1. World Health Organisation. Global Tuberculosis Report 2023. World Health Organisation; 2023.
4 Available: [https://iris.who.int/bitstream/handle/10665/373828/9789240083851-](https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1)
5 [eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1)

6 2. World Health Organization. What is DOTS? A guide to understanding the WHO-recommended
7 TB control strategy known as DOTS. Switzerland: World Health Organisation; Report No.:
8 WHO/CDS/CPC/TB/99.270. Available:
9 https://iris.who.int/bitstream/handle/10665/65979/WHO_CDS_CPC_TB_99.270.pdf

10 3. World Health Organisation. Consolidated guidelines on tuberculosis. Module 4: treatment.
11 Switzerland: World Health Organisation; 2022. Available:
12 <https://www.who.int/publications/i/item/9789240048126>

13 4. World Health Organisation. Adherence to long-term therapies: evidence for action. World
14 Health Organisation; 2003. Available: [https://www.paho.org/en/documents/who-adherence-](https://www.paho.org/en/documents/who-adherence-long-term-therapies-evidence-action-2003)
15 [long-term-therapies-evidence-action-2003](https://www.paho.org/en/documents/who-adherence-long-term-therapies-evidence-action-2003)

16 5. Ridho A, Alfian SD, van Boven JFM, Levita J, Yalcin EA, Le L, et al. Digital Health Technologies to
17 Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis:
18 Systematic Review of Randomized Controlled Trials. *J Med Internet Res.* 2022;24: e33062.
19 doi:10.2196/33062

20 6. Mohamed MS, Zary M, Kafie C, Chilala CI, Bahukudumbi S, Foster N, et al. The Impact of Digital
21 Adherence Technologies on Health Outcomes in Tuberculosis: A Systematic Review and Meta-
22 Analysis. 2024. doi:10.1101/2024.01.31.24302115

23 7. Holtrop JS, Estabrooks PA, Gaglio B, Harden SM, Kessler RS, King DK, et al. Understanding and
24 applying the RE-AIM framework: Clarifications and resources. *J Clin Transl Sci.* 2021;5: e126.
25 doi:10.1017/cts.2021.789

26 8. Bahukudumbi S, Chilala CI, Foster N, Patel B, Mohamed MS, Zary M, et al. Contextual factors
27 influencing implementation of tuberculosis digital adherence technologies: a scoping review
28 guided by the Re-AIM framework. *TBC.* 2024.

29 9. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for
30 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169: 467–
31 473. doi:10.7326/M18-0850

32 10. [Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive
33 package based on electronic medication monitors at improving treatment outcomes among
34 tuberculosis patients in Tibet: a multicentre randomised controlled trial. *The Lancet.* 2024;
35 \[S0140673623022705\]\(https://doi.org/10.1016/S0140-6736\(23\)02270-5\). doi:10.1016/S0140-6736\(23\)02270-5](#)

36 11. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method
37 for detecting bias in meta-analysis. *Int J Evid Based Healthc.* 2018;16: 195–203.
38 doi:10.1097/XEB.000000000000141

39 12. Shamim MA, Dwivedi P, Padhi BK. Beyond the funnel plot: The advantages of Doi plots and
40 prediction intervals in meta-analyses. *Asian J Psychiatr.* 2023;84: 103550.
41 doi:10.1016/j.ajp.2023.103550

- 1 13. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of
2 proportion studies, funnel plots were found to be an inaccurate method of assessing
3 publication bias. *J Clin Epidemiol*. 2014;67: 897–903. doi:10.1016/j.jclinepi.2014.03.003
- 4 14. Guzman K, Crowder R, Leddy A, Maraba N, Jennings L, Ahmed S, et al. Acceptability and
5 feasibility of digital adherence technologies for tuberculosis treatment supervision: A meta-
6 analysis of implementation feedback. 2023. doi:10.1101/2023.01.26.23284950
- 7 15. de Groot LM, Straetemans M, Maraba N, Jennings L, Gler MT, Marcelo D, et al. Time Trend
8 Analysis of Tuberculosis Treatment While Using Digital Adherence Technologies-An Individual
9 Patient Data Meta-Analysis of Eleven Projects across Ten High Tuberculosis-Burden Countries.
10 *Tropical Medicine and Infectious Disease*. 2022;7: 65. doi:10.3390/tropicalmed7050065
- 11 16. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of Electronic Reminders to
12 Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. Metcalfe
13 JZ, editor. *PLoS Med*. 2015;12: e1001876. doi:10.1371/journal.pmed.1001876
- 14 17. Wang N. Using electronic medication monitoring to guide differential management of
15 tuberculosis patients at the community level in China'. *BMC Infectious Diseases*. 2019;19: 1–9.
16 doi:10.1186/s12879-019-4521-2.
- 17 18. Wang N. Electronic medication monitor for people with tuberculosis: Implementation
18 experience from thirty counties in China'. *PLoS ONE*. 2020;15: 1–14.
19 doi:10.1371/journal.pone.0232337.
- 20 19. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, et al. Digital
21 adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-
22 randomized trial in Uganda. Suthar AB, editor. *PLoS Med*. 2021;18: e1003628.
23 doi:10.1371/journal.pmed.1003628
- 24 20. Zelnick JR, Daftary A, Hwang C, Labar AS, Boodhram R, Maharaj B, et al. Electronic Dose
25 Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis
26 and Human Immunodeficiency Virus. *Clinical infectious diseases : an official publication of the*
27 *Infectious Diseases Society of America*. 2021;73: e1901–e1910. Available:
28 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=6331669>
29 51
- 30 21. Casalme DJO, Marcelo DB, Dela Cuesta DM, Tonquin M, Frias MVG, Gler MT. Feasibility and
31 acceptability of asynchronous VOT among patients with MDR-TB. *The international journal of*
32 *tuberculosis and lung disease : the official journal of the International Union against*
33 *Tuberculosis and Lung Disease*. 2022;26: 760–765. doi:<https://dx.doi.org/10.5588/ijtld.21.0632>
- 34 22. Cross A, Gupta N, Liu B, Nair V, Kumar A, Kuttan R, et al. 99DOTS: A Low-Cost Approach to
35 Monitoring and Improving Medication Adherence. 10th International Conference on
36 Information and Communication Technologies and Development (ICTD). 2019. Available: <Go
37 to ISI>://WOS:000478678100015
- 38 23. Muyindike WR, Fatch R, Cheng DM, Emenyonu NI, Forman L, Ngabirano C, et al. Unhealthy
39 Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in
40 Persons With HIV in Southwestern Uganda. *Journal of Acquired Immune Deficiency Syndromes*.
41 2022;91: 460–468. doi:<https://dx.doi.org/10.1097/QAI.0000000000003082>

- 1 24. Mohammed S. Evaluating the Effectiveness of Interactive SMS Reminders on TB Drug
2 Compliance and Treatment. 2012. Available: <http://clinicaltrials>.
- 3 25. Liu X. Effectiveness of electronic reminders to improve medication adherence in tuberculosis
4 patients: a clusterrandomised trial. *PLoS Med.* 2015;12.
- 5 26. de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse RE,
6 et al. Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a
7 Resource-Limited Setting. *AIDS and behavior.* 2016;20: 1097–1107. Available:
8 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=61739](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=617396967)
9 [6967](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=617396967)
- 10 27. Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, et al. The effect of
11 text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. *The*
12 *European respiratory journal.* 2018;51. Available:
13 <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01930554/full>
- 14 28. Iribarren SJ, Milligan H, Chirico C, Goodwin K, Schnall R, Telles H, et al. Patient-centered mobile
15 tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot
16 randomized controlled trial exploring feasibility, acceptability and refinement needs. *Lancet*
17 *regional health Americas.* 2022;13. doi:<https://dx.doi.org/10.1016/j.lana.2022.100291>
- 18 29. Li X, Pang X, Zhang F. Evaluation of Mobile Application for the Management of Tuberculosis
19 Patients in Tianjin During 2019-2020. *Patient preference & adherence.* 2022;16: 321–329.
20 Available:
21 [https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NE](https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm&AN=35173417)
22 [WS=N&PAGE=fulltext&D=pmnm&AN=35173417](https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm&AN=35173417)
23 [http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:35173417&id=doi:10.](http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:35173417&id=doi:10.2147%2FPPA.S321289&issn=1177-889X&isbn=&volume=16&issue=&spage=321&pages=321-329&date=2022&title=Patient+preference+%26+adherence&atitle=Evaluation+of+Mobile+App+application+for+the+Management+of+Tuberculosis+Patients+in+Tianjin+During+2019-2020.&aulast=Li)
24 [2147%2FPPA.S321289&issn=1177-889X&isbn=&volume=16&issue=&spage=321&pages=321-](http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:35173417&id=doi:10.2147%2FPPA.S321289&issn=1177-889X&isbn=&volume=16&issue=&spage=321&pages=321-329&date=2022&title=Patient+preference+%26+adherence&atitle=Evaluation+of+Mobile+App+application+for+the+Management+of+Tuberculosis+Patients+in+Tianjin+During+2019-2020.&aulast=Li)
25 [329&date=2022&title=Patient+preference+%26+adherence&atitle=Evaluation+of+Mobile+App+ap](http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:35173417&id=doi:10.2147%2FPPA.S321289&issn=1177-889X&isbn=&volume=16&issue=&spage=321&pages=321-329&date=2022&title=Patient+preference+%26+adherence&atitle=Evaluation+of+Mobile+App+application+for+the+Management+of+Tuberculosis+Patients+in+Tianjin+During+2019-2020.&aulast=Li)
26 [plication+for+the+Management+of+Tuberculosis+Patients+in+Tianjin+During+2019-](http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:35173417&id=doi:10.2147%2FPPA.S321289&issn=1177-889X&isbn=&volume=16&issue=&spage=321&pages=321-329&date=2022&title=Patient+preference+%26+adherence&atitle=Evaluation+of+Mobile+App+application+for+the+Management+of+Tuberculosis+Patients+in+Tianjin+During+2019-2020.&aulast=Li)
27 [2020.&aulast=Li](http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:35173417&id=doi:10.2147%2FPPA.S321289&issn=1177-889X&isbn=&volume=16&issue=&spage=321&pages=321-329&date=2022&title=Patient+preference+%26+adherence&atitle=Evaluation+of+Mobile+App+application+for+the+Management+of+Tuberculosis+Patients+in+Tianjin+During+2019-2020.&aulast=Li)
- 28 30. Chen A, Kumar R, Baria RK, Shridhar PK, Subbaraman R, Thies W. Impact of the 99DOTS digital
29 adherence technology on tuberculosis treatment outcomes in North India: a pre-post study.
30 2022. doi:[10.21203/rs.3.rs-1900171/v1](https://doi.org/10.21203/rs.3.rs-1900171/v1)
- 31 31. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger C, Lamunu M, et al. Implementation,
32 feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB
33 in Uganda. 2022. doi:[10.1101/2022.10.10.22280911](https://doi.org/10.1101/2022.10.10.22280911)
- 34 32. Thakkar D, Piparva K, Lakkad S. A pilot project: 99DOTS information communication technology-
35 based approach for tuberculosis treatment in Rajkot district. *Lung India.* 2019;36: 108.
- 36 33. Acosta J, Flores P, Alarcon M, Grande-Ortiz M, Moreno-Exebio L, Puyen ZM. A randomised
37 controlled trial to evaluate a medication monitoring system for TB treatment. *International*
38 *journal of tuberculosis and lung disease.* 2022;26: 44-49. Available:
39 <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02361084/full>
- 40 34. Ailinger RL, Black PL, Lima-Garcia N. Use of electronic monitoring in clinical nursing research.
41 *Clinical Nursing Research.* 2008;17: 89–97. Available:
42 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=35147](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=351473988)
43 [3988](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=351473988)

- 1 35. Guo G, Sun L, Wushoue Q, Jia B, Yusufu M, Wen S, et al. eDOTS: a new system applied for
2 improving the treatment of pulmonary tuberculosis patients from Kashgar villages and Urumqi
3 streets in Xinjiang, China. In Review; 2021 Mar. doi:10.21203/rs.3.rs-279235/v1
- 4 36. Liu X, Thompson J, Dong H. Digital adherence technologies to improve tuberculosis treatment
5 outcomes in China: a cluster-randomised superiority trial. *Lancet Glob Health*. 2023;11: 693–
6 703.
- 7 37. Manyazewal T, Wuel Y, DP H, A F, VC M. Effectiveness of a digital medication event reminder and
8 monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled
9 trial. *BMC Med*. 2022;20. doi:10.1186/s12916-022-02521-y
- 10 38. Park S, Sentissi I, Gil SJ, Park WS, Oh B, Son AR, et al. Medication Event Monitoring System for
11 Infectious Tuberculosis Treatment in Morocco: A Retrospective Cohort Study. *International*
12 *Journal of Environmental Research & Public Health* [Electronic Resource]. 2019;16: 31.
13 Available:
14 <https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med16&AN=30709029>
15 <http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:30709029&id=doi:10.3390%2Fijerph16030412&issn=1660-4601&isbn=&volume=16&issue=3&spage=&pages=&date=2019&title=International+Journal+of+Environmental+Research+%26+Public+Health+%5BElectronic+Resource%5D&atitle=Medication+Event+Monitoring+System+for+Infectious+Tuberculosis+Treatment+in+Morocco%3A+A+Retrospective+Cohort+Study.&aulast=Park>
16
17
18
19
20
21
- 22 39. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of
23 treatment adherence and validation of alternative adherence measures in tuberculosis
24 patients: A pilot study. *Bulletin of the World Health Organization*. 2011;89: 632–639. Available:
25 <http://www.who.int/bulletin/volumes/89/9/11-086462.pdf>
26 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=362481734>
27
- 28 40. Velen K, Nguyen TA, Pham CD, Le HT, Nguyen HB, Dao BT, et al. The effect of medication event
29 reminder monitoring on treatment adherence of TB patients. *The international journal of*
30 *tuberculosis and lung disease : the official journal of the International Union against*
31 *Tuberculosis and Lung Disease*. 2023;27: 322–328. doi:<https://dx.doi.org/10.5588/ijtld.22.0500>
- 32 41. Story A. Smartphone-enabled video-observed versus directly observed treatment for
33 tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. *Lancet*.
34 2019;393: 1216–1224.
- 35 42. Bachina P, Lippincott CK, Perry A, Munk E, Maltas G, Bohr R, et al. Programmatic Adoption and
36 Implementation of Video-Observed Therapy in Minnesota: Prospective Observational Cohort
37 Study. *JMIR formative research*. 2022;6: e38247. doi:<https://dx.doi.org/10.2196/38247>
- 38 43. Bendiksen R. Use of video directly observed treatment for tuberculosis in Northern Norway.
39 *Tidsskr Nor Laegeforen*. 2020;140.
- 40 44. Chuck C. Enhancing management of tuberculosis treatment with video directly observed
41 therapy in New York City. *Int J Tuberc Lung Dis*. 2016;20: 588–593.
- 42 45. DeMaio J, Schwartz L, Cooley P, Tice A. The application of telemedicine technology to a directly
43 observed therapy program for tuberculosis: a pilot project. *Clin Infect Dis*. 2001;33: 2082–2084.

- 1 46. Garfein RS, Liu L, Cuevas-Mota J, Collins K, Catanzaro DG, Munoz F, et al. Evaluation of recorded
2 video-observed therapy for anti-tuberculosis treatment. *International Journal of Tuberculosis
3 and Lung Disease*. 2020;24: 520–525. Available:
4 [http://docserver.ingentaconnect.com/deliver/connect/iuatId/10273719/v24n5/s9.pdf?expires=
5 1609850012&id=0000&titleid=3764&checksum=6CAA5E57050319002E79685DABC39086
6 \[http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed22&NEWS=N&AN=20105
7 59172\]\(http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed22&NEWS=N&AN=2010559172\)](http://docserver.ingentaconnect.com/deliver/connect/iuatId/10273719/v24n5/s9.pdf?expires=1609850012&id=0000&titleid=3764&checksum=6CAA5E57050319002E79685DABC39086)
- 8 47. Garfein RS, Lin L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, et al. Tuberculosis
9 Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA.
10 *Emerging Infectious Diseases*. 2018;24: 1806–1815. Available:
11 [https://proxy.library.mcgill.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&
12 db=rzh&AN=131826871&site=ehost-live](https://proxy.library.mcgill.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=131826871&site=ehost-live)
- 13 48. Garfein RS, Collins K, Munoz F, Moser K, Cerecer-Callu P, Raab F, et al. Feasibility of tuberculosis
14 treatment monitoring by video directly observed therapy: A binational pilot study. *International
15 Journal of Tuberculosis and Lung Disease*. 2015;19: 1057–1064. Available:
16 [http://docstore.ingenta.com/cgi-
17 bin/ds_deliver/1/u/d/ISIS/82482727.1/iuatId/ijtId/2015/00000019/00000009/art00011/67CA3
18 E336BB6A93814394324052DC29D15D953CA4D.pdf?link=http://www.ingentaconnect.com/err
19 or/delivery&format=pdf
20 \[http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&AN=60563
21 5808\]\(http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&AN=605635808\)](http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/82482727.1/iuatId/ijtId/2015/00000019/00000009/art00011/67CA3E336BB6A93814394324052DC29D15D953CA4D.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf)
- 22 49. Holzman SB, Atre S, Sahasrabudhe T, Ambike S, Jagtap D, Sayyad Y, et al. Use of Smartphone-
23 Based Video Directly Observed Therapy (vDOT) in Tuberculosis Care: Single-Arm, Prospective
24 Feasibility Study. *JMIR Formative Research*. 2019;3: e13411. Available:
25 [https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NE
26 WS=N&PAGE=fulltext&D=pmnm4&AN=31456581
27 \[http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:31456581&id=doi:10.
28 2196%2F13411&issn=2561-
29 326X&isbn=&volume=3&issue=3&spage=e13411&pages=e13411&date=2019&title=JMIR+For
30 mative+Research&atitle=Use+of+Smartphone-
31 Based+Video+Directly+Observed+Therapy+%28vDOT%29+in+Tuberculosis+Care%3A+Single-
32 Arm%2C+Prospective+Feasibility+Study.&aulast=Holzman\]\(http://mcgill.on.worldcat.org/atoztitles/link?sid=OVID:medline&id=pmid:31456581&id=doi:10.2196%2F13411&issn=2561-326X&isbn=&volume=3&issue=3&spage=e13411&pages=e13411&date=2019&title=JMIR+Formative+Research&atitle=Use+of+Smartphone-Based+Video+Directly+Observed+Therapy+%28vDOT%29+in+Tuberculosis+Care%3A+Single-Arm%2C+Prospective+Feasibility+Study.&aulast=Holzman\)](https://proxy.library.mcgill.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm4&AN=31456581)
- 33 50. Holzman SB, Zenilman A, Shah M. Advancing patientcentered care in tuberculosis management:
34 a mixed-methods appraisal of video directly observed therapy. *Open Forum Infect Dis*. 2018;5.
- 35 51. Kumwichar P, Chongsuvivatwong V, Prappre T. Video-Observed Therapy With a Notification
36 System for Improving the Monitoring of Tuberculosis Treatment in Thailand: Usability Study.
37 *JMIR formative research*. 2022;6: e35994. doi:<https://dx.doi.org/10.2196/35994>
- 38 52. Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using Video Technology
39 to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month
40 Isoniazid and Rifapentine: An Implementation Study. *Journal of medical Internet research*.
41 2018;20: e287. Available:
42 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed19&NEWS=N&AN=62507
43 2001](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed19&NEWS=N&AN=625072001)

- 1 53. Lippincott CK, Perry A, Munk E, Maltas G, Shah M. Tuberculosis treatment adherence in the era
2 of COVID-19. *BMC Infectious Diseases*. 2022;22: 800. doi:[https://dx.doi.org/10.1186/s12879-](https://dx.doi.org/10.1186/s12879-022-07787-4)
3 [022-07787-4](https://dx.doi.org/10.1186/s12879-022-07787-4)
- 4 54. Mirsaedi M. Video directly observed therapy for treatment of tuberculosis is patient-oriented
5 and cost-effective. *Eur Respir J*. 2015;46: 871–874.
- 6 55. Olano-Soler H, Thomas D, Joglar O. Notes from the field: use of asynchronous video directly
7 observed therapy for treat- ment of tuberculosis and latent tuberculosis infection in a long-
8 term–care facility–Puerto Rico, 2016–2017. *MMWR Morb Mortal Wkly Rep*. 2017;66: 1386–
9 1387.
- 10 56. Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation
11 of video-observed therapy in an urban TB program in the United States. *International Journal of*
12 *Tuberculosis and Lung Disease*. 2021;25: 655–661. Available:
13 [https://www.ingentaconnect.com/contentone/iatld/ijtld/2021/00000025/00000008/art0001](https://www.ingentaconnect.com/contentone/iatld/ijtld/2021/00000025/00000008/art00011)
14 [1](https://www.ingentaconnect.com/contentone/iatld/ijtld/2021/00000025/00000008/art00011)
15 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=2013910](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=2013910983)
16 [983](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=2013910983)
- 17 57. Rajalahti I, Kreivi HR, Ollgren J, Vasankari T. Asynchronous video supported treatment of
18 tuberculosis is well adopted in a real-world setting - an observational study comparing two
19 distinct applications. *Infectious diseases (London, England)*. 2022; 04-Jan.
20 doi:<https://dx.doi.org/10.1080/23744235.2022.2160492>
- 21 58. Sekandi JN. Video directly observed therapy for supporting and monitoring adherence to
22 tuberculosis treatment in Uganda: a pilot cohort study. *ERJ Open Res*. 2020;6: 00175–02019.
- 23 59. Zhao A, Butala N, Luc CM, Feinn R, Murray TS. Telehealth Reduces Missed Appointments in
24 Pediatric Patients with Tuberculosis Infection. *Tropical Medicine and Infectious Disease*. 2022;7:
25 26. Available: <https://www.mdpi.com/journal/tropicalmed>
26 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2015748](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2015748495)
27 [495](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2015748495)
- 28 60. Krueger K, Ruby D, Cooley P, Montoya B, Exarchos A, Djojonegoro BM, et al. Videophone
29 utilization as an alternative to directly observed therapy for tuberculosis. *International Journal of*
30 *Tuberculosis and Lung Disease*. 2010;14: 779–781. Available:
31 [http://docstore.ingenta.com/cgi-](http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/56720831.1/iatld/ijtld/2010/00000014/00000006/art00019/D4EA7E12F41A958E1273633883806F82439C816399.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf)
32 [bin/ds_deliver/1/u/d/ISIS/56720831.1/iatld/ijtld/2010/00000014/00000006/art00019/D4EA7](http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/56720831.1/iatld/ijtld/2010/00000014/00000006/art00019/D4EA7E12F41A958E1273633883806F82439C816399.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf)
33 [E12F41A958E1273633883806F82439C816399.pdf?link=http://www.ingentaconnect.com/error](http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/56720831.1/iatld/ijtld/2010/00000014/00000006/art00019/D4EA7E12F41A958E1273633883806F82439C816399.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf)
34 [/delivery&format=pdf](http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/56720831.1/iatld/ijtld/2010/00000014/00000006/art00019/D4EA7E12F41A958E1273633883806F82439C816399.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf)
35 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=35883](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=358833241)
36 [3241](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=358833241)
- 37 61. Browne SH. Wirelessly observed therapy compared to directly observed therapy to confirm and
38 support tuberculosis treatment adherence: a randomized controlled trial. *PLoS Med*. 2019;16.
- 39 62. O’Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, et al. Bedaquiline adherence
40 measured by electronic dose monitoring predicts clinical outcomes in the treatment of patients
41 with multidrug-resistant tuberculosis and HIV/AIDS. *Journal of acquired immune deficiency*
42 *syndromes (1999)*. 2022. Available:


- 1 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=6373259>
2 92
- 3 63. Wade VA, Karnon J, Elliott JA, Hiller JE. Home Videophones Improve Direct Observation in
4 Tuberculosis Treatment: A Mixed Methods Evaluation. *PLoS ONE*. 2012;7: e50155. Available:
5 [http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2](http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0050155&representation=PDF)
6 [Fjournal.pone.0050155&representation=PDF](http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0050155&representation=PDF)
7 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed13&NEWS=N&AN=36620>
8 7260
- 9 64. Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a Comprehensive
10 Package Based on Electronic Medication Monitors at Improving Treatment Outcomes Among
11 Tuberculosis Patients in Tibet: A Multi-Centre Randomised Controlled Trial. 2023.
12 doi:10.2139/ssrn.4387313
- 13 65. Hermans SM. Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection
14 in Uganda. *Patient Prefer Adherence*. 2017;11: 1479–1487.
- 15 66. Dessie Gashu K, Nurhussien F, Mamuye A, Alemu Gelaye K, Tilahun B. Developing and Piloting
16 TB Medication and Refilling Reminder System in Ethiopia. *Studies in health technology and*
17 *informatics*. 2020;270: 1251–1252. Available:
18 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed21&NEWS=N&AN=63216>
19 9171
- 20 67. Katende KK, Amiyo MR, Nabukeera S, Mugisa I, Kaggwa P, Namatovu S, et al. Design,
21 development, and testing of a voice-text mobile health application to support Tuberculosis
22 medication adherence in Uganda. *PloS one*. 2022;17: e0274112.
23 doi:<https://dx.doi.org/10.1371/journal.pone.0274112>
- 24 68. Mohammed S, Glennerster R, Khan AJ. Impact of a Daily SMS Medication Reminder System on
25 Tuberculosis Treatment Outcomes: A Randomized Controlled Trial. Gao L, editor. *PLoS ONE*.
26 2016;11: e0162944. doi:10.1371/journal.pone.0162944
- 27 69. Gashu KD, Gelaye KA, Lester R, Tilahun B. Effect of a phone reminder system on patient-
28 centered tuberculosis treatment adherence among adults in Northwest Ethiopia: a randomised
29 controlled trial. *BMJ Health Care Inform*. 2021;28.
- 30 70. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger CA, Lamunu M, et al.
31 Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for
32 drug-susceptible TB in Uganda. Mathur P, editor. *PLOS Digit Health*. 2023;2: e0000138.
33 doi:10.1371/journal.pdig.0000138
- 34 71. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with
35 treatment adherence in a randomised trial of latent tuberculosis infection treatment.
36 *International journal of tuberculosis and lung disease*. 2010;14: 551-559. Available:
37 <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00748488/full>
- 38 72. Wang N, Shewade HD, Thekkur P, Zhang H, Yuan Y, Wang X, et al. Do electronic medication
39 monitors improve tuberculosis treatment outcomes? Programmatic experience from China.
40 *PLoS ONE*. 2020;15: e0242112. Available:
41 <https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0242112&type=printabl>
42 e

- 1 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed22&NEWS=N&AN=20085>
2 97080
- 3 73. Hoffman JA. Mobile direct observation treatment for tuberculosis patients: a technical
4 feasibility pilot using mobile phones in Nairobi, Kenya. *Am J Prev Med.* 2010;39: 78–80.
- 5 74. Guo X. A comprehensive app that improves tuberculosis treatment management through
6 video-observed therapy: usability study. *JMIR Mhealth Uhealth.* 2020;8.
- 7 75. Nguyen TA, Pham MT, Nguyen TL, Nguyen VN, Pham DC, Nguyen BH, et al. Video Directly
8 Observed Therapy to Support Adherence with Treatment for Tuberculosis in Vietnam: A
9 Prospective Cohort Study. *International Journal of Infectious Diseases.* 2017;65: 85–89.
10 doi:10.1016/j.ijid.2017.09.029
- 11 76. Bassett I. Sizanani: a randomized trial of health system navigators to improve linkage to HIV and
12 TB care in South Africa. *J Acquir Immune Defic Syndr.* 2016;73: 154–160.
- 13 77. Cocozza AM, Linh NN, Nathavitharana RR, Ahmad U, Jaramillo E, Gargioni GEM, et al. An
14 assessment of current tuberculosis patient care and support policies in high-burden countries.
15 *International Journal of Tuberculosis and Lung Disease.* 2020;24: 36–42. Available:
16 <https://www.ingentaconnect.com/contentone/iatld/ijtd/2020/00000024/00000001/art0000>
17 8
18 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed21&NEWS=N&AN=20071>
19 51037
- 20 78. Macaraig M, Lobato MN, McGinnis Pilote K, Wegener D. A National Survey on the Use of
21 Electronic Directly Observed Therapy for Treatment of Tuberculosis. *Journal of public health*
22 *management and practice : JPHMP.* 2018;24: 567–570. Available:
23 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed19&NEWS=N&AN=62413>
24 1371
- 25 79. Wang X, Jiang H, Wang X, Liu H, Zhou L, Lu X. ESMPE: a combined strategy for school
26 tuberculosis prevention and control proposed by Dalian, China. *PLoS One.* 2017;12: 0185646.
- 27 80. Subbaraman R. Digital adherence technologies for the management of tuberculosis therapy:
28 mapping the landscape and research priorities. *BMJ Glob Health.* 2018;3.
- 29 81. Zary M, Mohamed MS, Kafie C, Chilala CI, Bahukudumbi S, Foster N, et al. The performance of
30 digital technologies for measuring tuberculosis medication adherence: a systematic review.
31 *MedRxiv.* doi:<https://doi.org/10.1101/2024.05.24.24307886>
- 32 82. Saunders MJ, Wingfield T, Tovar MA, Herlihy N, Rocha C, Zevallos K, et al. Mobile phone
33 interventions for tuberculosis should ensure access to mobile phones to enhance equity - a
34 prospective, observational cohort study in Peruvian shantytowns. *Trop Med Int Health.*
35 2018;23: 850–859. doi:10.1111/tmi.13087
- 36 83. Boutilier JJ, Yoeli E, Rathouser J, Owiti P, Subbaraman R, Jì?nasson JO. Can digital adherence
37 technologies reduce inequity in tuberculosis treatment success? Evidence from a randomised
38 controlled trial. *BMJ global health.* 2022;7. doi:10.1136/bmjgh-2022-010512
- 39 84. Li W, Su M, Zhang W, Fan X, Li R, Gao Y, et al. Barriers and facilitators of implementing electronic
40 monitors to improve adherence and health outcomes in tuberculosis patients: protocol for a

- 1 systematic review based on the Consolidated Framework for Implementation Research. Health
2 Res Policy Syst. 2023;21: 115. doi:10.1186/s12961-023-01054-x
- 3 85. De Moel-Mandel C, Lynch C, Issaka A, Braver J, Zisis G, Carrington MJ, et al. Optimising the
4 implementation of digital-supported interventions for the secondary prevention of heart
5 disease: a systematic review using the RE-AIM planning and evaluation framework. BMC Health
6 Serv Res. 2023;23: 1347. doi:10.1186/s12913-023-10361-6
- 7 86. Yoshida Y, Patil SJ, Brownson RC, Boren SA, Kim M, Dobson R, et al. Using the RE-AIM
8 framework to evaluate internal and external validity of mobile phone-based interventions in
9 diabetes self-management education and support. Journal of the American Medical Informatics
10 Association. 2020;27: 946–956. doi:10.1093/jamia/ocaa041
- 11 87. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for
12 Systematic Reviews of Interventions. 6.4. Chichester, UK: John Wiley & Sons; 2023.
- 13


Figure 1: measures of Reach A – proportion with TB or *M.tuberculosis* infection, eligible to use the DAT

a: proportion with cell phone access, stratified by country income level



Footnote:
 1. * studies where the DAT was exclusively smartphones
 2. Daftary (2017) a small convenient sample for qualitative study from a larger trial
 3. Guzman 1 (2023) was a 98/0/13 arm in a multi-country study
 4. Guzman 2 (2023) was an eviMed (pillbox) arm in a multi-country study


b: proportion with phone/SMS issues that excluded the person with TB being offered the DAT, stratified by country income-level



Footnote:
 Problems with phone/SMS were: being unable to SMS; problems with phone credit; problems with cellular network


Figure 2: measures of Reach B – proportion of people with TB or *M.tuberculosis* infection eligible to use the DAT, who exhibit any engagement

a: proportion agreeing to use the DAT, stratified by DAT type



Footnote:
 1. includes patients currently on/completed treatment
 2. includes patients currently on treatment
 3. LTBI study

b: proportion of people with TB using the DAT at least once, stratified by DAT type



Footnote:
 1. denominator of those who were sent messages
 2. denominator of those who randomized
 3. response from patient or family member
 4. response from patient only
 5. Clustering has been ignored for the 95% CI
 6. started in first treatment month
 7. started at any timepoint

Figure 3: Percentage of engagement by digital adherence technology type (Reach C)
[54 observations]

